First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study (OliGRAIL)

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: 1268edcb52fc85df4446a9aa63f580940252c4e7
First added on: Mar 21, 2025